A method for constructing a mouse model of allergic rhinitis

Abstract

This invention discloses a method for constructing a mouse model of allergic rhinitis. The method includes the following steps: selecting BALB / c mice for feeding; sensitizing the mice by intraperitoneal injection of physiological saline containing casein, lactose, and aluminum hydroxide, once a day for 6-8 consecutive days; after the intraperitoneal injection is completed, administering physiological saline containing casein and lactose to the mice via nasal drops at intervals, once a day for 6-8 consecutive days, while simultaneously administering olive oil containing toluene diisocyanate to the mice via nasal drops during the intervals; this invention's method, by limiting each step and parameter, enables the rapid construction of a mouse model of allergic rhinitis, requiring only about two weeks. Furthermore, this invention's method is simple and easy to implement, with a high success rate and survival rate.

Description

Technical Field

[0001] This invention relates to the field of mouse model construction technology, and specifically to a method for constructing a mouse model of allergic rhinitis. Background Technology

[0002] Allergic rhinitis (AR), also known as hypersensitive rhinitis, is a chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) and involves the body's immune cells and cytokines after susceptible individuals are exposed to allergens. The main symptoms are episodic sneezing, runny nose, and nasal congestion.

[0003] Currently, disease research requires standard patients, but due to medical protection and legal requirements, many medical research studies cannot be conducted on real patients. This necessitates replicating diseases in laboratory animals to establish relatively standardized animal models. Mice, due to their small size, rapid reproduction, and ease of rearing, are commonly used laboratory animals in medical research, and many disease models have been successfully replicated in them. Allergic rhinitis is a common respiratory disease in clinical practice, but due to environmental factors and animal strain, replicating a mouse model of allergic rhinitis is often difficult and time-consuming.

[0004] In view of this, the present invention is hereby proposed. Summary of the Invention

[0005] The purpose of this invention is to provide a method for constructing a mouse model of allergic rhinitis, which can quickly construct a mouse model of allergic rhinitis with a high success rate.

[0006] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted:

[0007] The first aspect of this invention provides a method for constructing a mouse model of allergic rhinitis, the method comprising the following steps:

[0008] (a) Select BALB / c mice for feeding;

[0009] (b) Sensitize mice by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide for 6 to 8 consecutive days, once a day;

[0010] (c) After the intraperitoneal injection was completed, mice were given intranasal drops of physiological saline containing casein and lactose at intervals, once a day for 6 to 8 days. At the same time, mice were given intranasal drops of olive oil containing toluene diisocyanate during the intervals.

[0011] Preferably, in step (b), the physiological saline containing casein, lactose, and aluminum hydroxide has a casein concentration of 6%–8%, a lactose concentration of 8%–10%, and an aluminum hydroxide concentration of 8%–12%.

[0012] Preferably, in step (b), the injection volume is 0.2 to 0.3 ml each time.

[0013] Preferably, in step (c), the casein concentration in the physiological saline containing casein and lactose is 10%–15% and the lactose concentration is 12%–15%.

[0014] Preferably, in step (c), the amount of physiological saline containing casein and lactose administered as nasal drops is 0.04 to 0.06 ml per nostril.

[0015] Preferably, in step (c), the interval is 1 day.

[0016] Preferably, the toluene diisocyanate content in the olive oil containing toluene diisocyanate is 0.5% to 1% by mass.

[0017] Preferably, the olive oil containing toluene diisocyanate is administered as nasal drops once daily, with 0.04 to 0.06 ml added to each nostril each time.

[0018] Compared with the prior art, the beneficial effects of the present invention include at least the following:

[0019] The construction method of this invention enables the rapid construction of a mouse model of allergic rhinitis by limiting each step and parameter, with a construction time of only about two weeks. In addition, the construction method of this invention is simple and easy to implement, with a high success rate and survival rate. Detailed Implementation

[0020] The embodiments of the technical solution of the present invention will be described in detail below with reference to the examples. The following embodiments are only used to illustrate the technical solution of the present invention more clearly, and are therefore only examples, and should not be used to limit the scope of protection of the present invention.

[0021] It should be noted that, unless otherwise stated, the technical or scientific terms used in this application should have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.

[0022] This invention provides a method for constructing a mouse model of allergic rhinitis, the method comprising the following steps:

[0023] (a) Select BALB / c mice for feeding;

[0024] (b) Sensitize mice by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide for 6 to 8 consecutive days, once a day;

[0025] (c) After the intraperitoneal injection was completed, mice were given intranasal drops of physiological saline containing casein and lactose at intervals, once a day for 6 to 8 days. At the same time, mice were given intranasal drops of olive oil containing toluene diisocyanate during the intervals.

[0026] The construction method of this invention enables the rapid construction of a mouse model of allergic rhinitis by limiting each step and parameter, with a construction time of only about two weeks. In addition, the construction method of this invention is simple and easy to implement, with a high success rate and survival rate.

[0027] To improve the success rate of construction, in one embodiment, in step (b), the physiological saline containing casein, lactose, and aluminum hydroxide has a casein mass concentration of 6% to 8%, a lactose mass concentration of 8% to 10%, and an aluminum hydroxide mass concentration of 8% to 12%.

[0028] In one embodiment, in step (b), the injection volume is 0.2 to 0.3 ml each time.

[0029] In one embodiment, in step (c), the casein mass concentration in the physiological saline containing casein and lactose is 10%–15%, and the lactose mass concentration is 12%–15%.

[0030] In one embodiment, in step (c), the amount of physiological saline containing casein and lactose is 0.04 to 0.06 ml per nostril.

[0031] By controlling the above parameters, the success rate and survival rate of constructing a mouse model of allergic rhinitis can be improved.

[0032] In one embodiment, the interval in step (c) is 1 day.

[0033] In one embodiment, the toluene diisocyanate content in the olive oil containing toluene diisocyanate is 0.5% to 1% by mass.

[0034] In one embodiment, the olive oil containing toluene diisocyanate is administered as nasal drops once daily, with 0.04 to 0.06 ml added to each nostril each time.

[0035] The technical solution of the present invention will be further described in detail below through specific embodiments.

[0036] Example 1

[0037] This embodiment describes a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0038] (a) Select BALB / c mice for feeding;

[0039] (b) The mice were sensitized by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide for 6 consecutive days, once a day, with each injection being 0.3 ml. The casein, lactose and aluminum hydroxide contained 8% casein, 8% lactose and 12% aluminum hydroxide.

[0040] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing casein and lactose every other day, once a day, with a volume of 0.04 ml per nostril, for 8 consecutive days. At the same time, during the interval, mice were given nasal drops of olive oil containing toluene diisocyanate once a day, with a volume of 0.04 ml per nostril each time. The casein concentration in the physiological saline containing casein and lactose was 15% and the lactose concentration was 15%; the toluene diisocyanate content in the olive oil containing toluene diisocyanate was 1%.

[0041] Example 2

[0042] This embodiment describes a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0043] (a) Select BALB / c mice for feeding;

[0044] (b) The mice were sensitized by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide for 8 consecutive days, once a day, with each injection being 0.2 ml. The casein concentration in the physiological saline containing casein, lactose and aluminum hydroxide was 6%, the lactose concentration was 10%, and the aluminum hydroxide concentration was 8%.

[0045] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing casein and lactose every other day, once a day, with a volume of 0.06 ml per nostril, for 6 consecutive days. At the same time, during the interval, mice were given nasal drops of olive oil containing toluene diisocyanate once a day, with a volume of 0.06 ml per nostril each time. The casein concentration in the physiological saline containing casein and lactose was 10%, and the lactose concentration was 12%. The toluene diisocyanate content in the olive oil containing toluene diisocyanate was 0.5%.

[0046] Example 3

[0047] This embodiment describes a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0048] (a) Select BALB / c mice for feeding;

[0049] (b) Sensitize mice by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide for 7 consecutive days, once a day, with each injection being 0.25 ml. The casein concentration in the physiological saline containing casein, lactose and aluminum hydroxide was 7%, the lactose concentration was 9%, and the aluminum hydroxide concentration was 10%.

[0050] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing casein and lactose every other day, once a day, with a volume of 0.05 ml per nostril, for 7 consecutive days. At the same time, during the interval, mice were given nasal drops of olive oil containing toluene diisocyanate once a day, with a volume of 0.05 ml per nostril each time. The casein concentration in the physiological saline containing casein and lactose was 12%, and the lactose concentration was 14%. The toluene diisocyanate content in the olive oil containing toluene diisocyanate was 0.8%.

[0051] Comparative Example 1

[0052] This comparative example illustrates a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0053] (a) Select BALB / c mice for feeding;

[0054] (b) The mice were sensitized by intraperitoneal injection of physiological saline containing OVA, lactose and aluminum hydroxide for 7 consecutive days, once a day, with each injection being 0.25 ml. The physiological saline containing OVA, lactose and aluminum hydroxide had a mass concentration of 7% OVA, 9% lactose and 10% aluminum hydroxide.

[0055] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing OVA and lactose every other day, once a day, with a volume of 0.05 ml per nostril, for 7 consecutive days. At the same time, during the interval, mice were given nasal drops of olive oil containing toluene diisocyanate once a day, with a volume of 0.05 ml per nostril each time. The physiological saline containing OVA and lactose had a casein concentration of 12% and a lactose concentration of 14% by mass. The olive oil containing toluene diisocyanate had a toluene diisocyanate content of 0.8% by mass.

[0056] Comparative Example 2

[0057] This comparative example illustrates a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0058] (a) Select BALB / c mice for feeding;

[0059] (b) Sensitize mice by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide for 7 consecutive days, once a day, with each injection being 0.25 ml. The casein concentration in the physiological saline containing casein, lactose and aluminum hydroxide was 7%, the lactose concentration was 9%, and the aluminum hydroxide concentration was 10%.

[0060] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing casein and lactose once a day, with a volume of 0.05 ml per nostril for 7 consecutive days. The casein concentration in the physiological saline containing casein and lactose was 12% and the lactose concentration was 14%.

[0061] Comparative Example 3

[0062] This comparative example illustrates a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0063] (a) Select BALB / c mice for feeding;

[0064] (b) The mice were sensitized by intraperitoneal injection of physiological saline containing casein and aluminum hydroxide for 7 consecutive days, once a day, with each injection being 0.25 ml. The casein in the physiological saline containing casein and aluminum hydroxide had a mass concentration of 7% and the aluminum hydroxide had a mass concentration of 10%.

[0065] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing casein once a day at one-day intervals, with a nasal volume of 0.05 ml per nostril for 7 consecutive days. At the same time, during the intervals, mice were given nasal drops of olive oil containing toluene diisocyanate once a day, with 0.05 ml added to each nostril each time. The casein concentration in the physiological saline containing casein was 12% by mass, and the toluene diisocyanate content in the olive oil containing toluene diisocyanate was 0.8% by mass.

[0066] Comparative Example 4

[0067] This comparative example illustrates a method for constructing a mouse model of allergic rhinitis, which includes the following steps:

[0068] (a) Select BALB / c mice for feeding;

[0069] (b) Mice were sensitized by intraperitoneal injection of physiological saline containing lactose and aluminum hydroxide for 7 consecutive days, once a day, with each injection being 0.25 ml. The physiological saline containing lactose and aluminum hydroxide had a mass concentration of 9% lactose and a mass concentration of 10% aluminum hydroxide.

[0070] (c) After the intraperitoneal injection was completed, mice were given nasal drops of physiological saline containing lactose every other day, once a day, with a volume of 0.05 ml per nostril, for 7 consecutive days. At the same time, during the interval, mice were given nasal drops of olive oil containing toluene diisocyanate once a day, with 0.05 ml added to each nostril each time. The lactose concentration in the physiological saline containing lactose was 14% by mass, and the toluene diisocyanate content in the olive oil containing toluene diisocyanate was 0.8% by mass.

[0071] Experimental Example

[0072] Allergic rhinitis mouse models were constructed according to the construction methods of Example 3 and Comparative Examples 1-4, respectively; 20 mice were constructed using each construction method.

[0073] The allergic rhinitis mice were scored using an allergy response index. The scoring criteria were based on the severity and frequency of nasal itching, sneezing, and runny nose within 20 minutes after the last nasal instillation. The scoring criteria are shown in Table 1.

[0074] Table 1

[0075]

[0076] The model is successfully constructed if the scores of all symptoms are summed and the total score is greater than 5.

[0077] The number of successful mouse models of allergic rhinitis constructed using different methods was counted, and the results are shown in Table 2.

[0078] Table 2

[0079] Group Quantity (pieces) Example 3 19 Comparative Example 1 11 Comparative Example 2 14 Comparative Example 3 12 Comparative Example 4 7

[0080] As shown in Table 2:

[0081] Compared with the comparative example, the construction method of this application embodiment can better construct a mouse model of allergic rhinitis with a high success rate.

[0082] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and specification of the present invention.

Claims

1. A method for constructing a mouse model of allergic rhinitis, characterized by, It comprises the following steps: (a) selecting BALB / c mice for breeding; (b) sensitizing the mice by intraperitoneal injection of physiological saline containing casein, lactose and aluminum hydroxide, continuously injecting for 6-8 days, once a day; (c) after the intraperitoneal injection is completed, the mice are intermittently dripped with physiological saline containing casein and lactose, once a day, continuously for 6-8 days, and at the same time, the mice are dripped with toluene diisocyanate olive oil during the interval; In step (b), the mass concentration of casein in the physiological saline containing casein, lactose and aluminum hydroxide is 6%-8%, the mass concentration of lactose is 8%-10%, and the mass concentration of aluminum hydroxide is 8%-12%; the injection amount is 0.2-0.3 ml each time; In step (c), the mass concentration of casein in the physiological saline containing casein and lactose is 10%-15%, and the mass concentration of lactose is 12%-15%; the dripping amount of the physiological saline containing casein and lactose is 0.04-0.06 ml per nostril; the interval time is 1 day; The mass content of toluene diisocyanate in the toluene diisocyanate olive oil is 0.5%-1%; The toluene diisocyanate olive oil is dripped once a day, and 0.04-0.06 ml is added to each nostril each time.

Images